Objective. Cartilage damage and subchondral bone changes are closely connected in osteoarthritis. Nevertheless, how these processes are interlinked is, to date, incompletely understood. This study was undertaken to investigate the mechanistic role of a cartilage-derived protein, upper zone of growth plate and cartilage matrix-associated protein (UCMA), in osteoarthritis-related cartilage and bone changes.
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Objective. Cartilage damage and subchondral bone changes are closely connected in osteoarthritis. Nevertheless, how these processes are interlinked is, to date, incompletely understood. This study was undertaken to investigate the mechanistic role of a cartilage-derived protein, upper zone of growth plate and cartilage matrix-associated protein (UCMA), in osteoarthritis-related cartilage and bone changes.
Methods. UCMA expression was assessed in healthy and osteoarthritic human and mouse cartilage. For analysis of cartilage and bone changes, osteoarthritis was induced by destabilization of the medial meniscus (DMM) in wild-type (WT) and Ucma-deficient mice. UCMA-collagen interactions, the effect of UCMA on aggrecanase activity, and the impact of recombinant UCMA on osteoclast differentiation were studied in vitro.
Results. UCMA was found to be overexpressed in human and mouse osteoarthritic cartilage. DMM-triggered cartilage changes, including increased structural damage, proteoglycan loss, and chondrocyte cell death, were aggravated in Ucma-deficient mice compared to WT littermates, thereby demonstrating the potential chondroprotective effects of UCMA. Moreover, UCMA inhibited ADAMTSdependent aggrecanase activity and directly interacted with cartilage-specific collagen types. In contrast, osteoarthritisrelated bone changes were significantly reduced in Ucmadeficient mice, showing less pronounced osteophyte formation and subchondral bone sclerosis. Mechanistically, UCMA directly promoted osteoclast differentiation in vitro.
Conclusion. UCMA appears to link cartilage with bone changes in osteoarthritis by supporting cartilage integrity as an endogenous inhibitor of aggrecanases while also promoting osteoclastogenesis and subchondral bone turnover. Thus, UCMA represents an important link between cartilage and bone in osteoarthritis.
Articular cartilage degeneration is a hallmark of osteoarthritis. In contrast to other mesenchymal tissues, damaged cartilage does not regenerate sufficiently, even if the trigger for cartilage loss can be controlled by clinical intervention. To date, a number of factors involved in osteoarthritis-related cartilage degradation have been identified, including the activation of aggrecanases (ADAMTS-4 and ADAMTS-5) and matrix metalloproteinases (MMPs) (1, 2) . Moreover, chondrocytes in articular cartilage hardly proliferate, and there is no efficient external cell supply for cartilage renewal (3) . Therefore, increased chondrocyte apoptosis, often observed in osteoarthritis, may promote cartilage degeneration (4) (5) (6) (7) . Together, these events lead to an imbalance in matrix turnover and, eventually, to cartilage matrix degradation. Subchondral bone sclerosis and osteophyte formation are additional prominent features of osteoarthritis (8, 9) . Since progression of cartilage damage and subchondral bone alterations coincide during osteoarthritis, it has been difficult to elucidate how these processes in cartilage and bone are interlinked. Nevertheless, some studies suggest that targeting bone sclerosis in osteoarthritis may be beneficial for cartilage integrity (10, 11) .
Despite recent advances in understanding the pathophysiology of osteoarthritis, there are currently no curative approaches available for the treatment of osteoarthritis. Therefore, unraveling the molecular mechanisms of cartilage degradation and subchondral bone alterations may provide important advances in the development of novel therapies, which would prevent further cartilage loss andideally-induce tissue repair. Recently, we introduced a novel chondrocyte-specific protein, upper zone of growth plate and cartilage matrix-associated protein (UCMA), that is secreted into the cartilage matrix (12) (13) (14) . Whereas knockdown of Ucma in zebrafish embryos leads to craniofacial malformations, suggesting a role of UCMA in skeletal development, Ucma-deficient mice develop normally (12, 15) . Thus, the physiologic function of UCMA in mammals has largely remained unknown.
Since the function of extracellular matrix proteins often has been revealed only under challenging conditions, we considered that UCMA might play a relevant role in joint integrity under pathologic conditions. Therefore, we studied the impact of UCMA on osteoarthritis. In the present study, we demonstrated that UCMA protein expression is up-regulated in osteoarthritic cartilage. In a mouse model of osteoarthritis induced by surgical destabilization of the medial meniscus (DMM), Ucma-deficient mice exhibited exacerbated cartilage degradation compared to wild-type (WT) littermates, thereby indicating the potential chondroprotective properties of UCMA. Supporting this notion, we demonstrated that UCMA is an efficient inhibitor of aggrecanases. In contrast to this chondroprotective effect, osteoarthritis-triggered bone alterations were substantially reduced in Ucma-deficient mice, being attributable to reduced differentiation of osteoblasts and osteoclasts. Taken together, these findings suggest a dual role of UCMA in osteoarthritis, influencing both cartilage proteoglycan degradation and subchondral bone changes.
MATERIALS AND METHODS
Mice. All experiments were performed with the approval of the local ethics authorities (University of Erlangen-Nuremberg and the Government of Mittelfranken, Ansbach, Germany) and according to the regulations of the animal facilities in Germany.
Induction of experimental osteoarthritis in mice. Sham surgery and DMM through surgical transection of the medial meniscotibial ligament were performed in mice at ages 8 weeks or 12 weeks, as previously described (16) . DMM and sham operations were carried out in separate groups, with both legs undergoing surgery. At 4 weeks postsurgery (n 5 3 or n 5 4 mice per group) or 8 weeks postsurgery (n 5 5 or n 5 6 mice per group), mice were killed and frontal paraffin sections (4 mm) of the knees were prepared. The second knee was used for RNA preparation or micro-computed tomography (micro-CT) analyses.
Human cartilage samples. Samples of human cartilage were obtained from the knee joints of healthy human subjects during autopsy (n 5 3). Osteoarthritic cartilage specimens were obtained from osteoarthritis patients (n 5 3) who had undergone total knee joint arthroplasty at the University Hospital Erlangen. Each patient gave informed consent prior to surgery, and the institutional ethics committee approved the study protocol.
Histology. Scoring of the histologic severity of osteoarthritis was performed according to Osteoarthritis Research Society International (OARSI) recommendations, in which all 4 quadrants of the stifle joint (medial and lateral femoral condyles, and medial and lateral tibial plateaus; 8 of the most affected sections per joint) were scored in multiple-step sections through the complete joint (17) . Maximal scores from all 4 quadrants were cumulated, as reported previously (16) . Proteoglycan loss was quantified by determining the proportion of articular cartilage that was negative for Safranin O staining (17) . Osteophytes, subchondral bone plate thickness, and bone volume of the primary spongiosa were assessed on Safranin O-stained or hematoxylin and eosin-stained sections of the articular cartilage. Osteoclast and osteoblast numbers were determined on tartrate-resistant acid phosphatase (TRAP)-stained and Goldner's trichromestained tissue sections. Quantification was carried out using ImageJ software or an OsteoMeasure system (OsteoMetrics) (16, 18) . Micro-CT analysis of the tibiae was performed in a manner as recently described (18) . Bone volume was measured in the trabecular bone of the metaphysis (the first 4 mm below the primary spongiosa). All analyses were performed in a blinded manner (n 5 3-4 mice per group at 4 weeks postsurgery, n 5 5-6 mice per group at 8 weeks postsurgery).
Immunohistochemistry. Immunohistochemical detection of UCMA in the cartilage samples was performed as previously reported (12) . After antigen retrieval with hyaluronidase and blocking, detection of UCMA was performed using a UCMAspecific antibody (ab-2, 1:500) and a SignalStain Boost immunohistochemistry detection reagent (HRP, rabbit; Cell Signaling Technologies) with diaminobenzidine. NITEGE and VDIPEN neoepitopes were detected similarly, using a rabbit anti-NITEGE antibody (Ab1320, 1:1,000; IBEX Pharmaceuticals) or affinitypurified anti-VDIPEN antibody (19) , followed by staining with a biotinylated goat anti-rabbit IgG antibody or avidin-peroxidase (Vector Laboratories), respectively. Cell death analysis in sections of articular cartilage was performed by TUNEL staining using an In Situ Cell Death Detection Kit (Roche) (n 5 3-4 mice per group at 4 weeks postsurgery, n 5 5-6 mice per group at 8 weeks postsurgery).
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Gene expression analyses. Total RNA was extracted from murine epiphyseal cartilage (n 5 3 mice per group), total knee joints (n 5 5 mice per group), or articular cartilage (n 5 6 mice per group) using an RNeasy Fibrous Tissue Mini Kit (Qiagen). Complementary DNA was synthesized using SuperScript II reverse transcriptase (Invitrogen), and messenger RNA (mRNA) expression of each gene, relative to the values for cyclophilin A, was quantified by real-time reverse transcriptionpolymerase chain reaction, as previously described (13) Protein interaction studies. Recombinant His-FLAGtagged UCMA was episomally expressed in HEK 293-EpsteinBarr nuclear antigen cells and purified from conditioned medium by affinity chromatography on nickel-nitrilotriacetic acidSepharose (Qiagen), as reported previously (13) . Different collagen types (all derived from chicken sources by pepsin extraction) were immobilized on PVDF membranes by vacuum blotting. After blocking with bovine serum albumin (BSA), the membranes were incubated in recombinant UCMA (100 ng/ml); after washing, bound UCMA was detected using rabbit anti-UCMA (UCMA-1, 1:1,000) or mouse anti-FLAG (1:1,000) antibodies (both from Sigma-Aldrich) or an anti-rabbit or anti-mouse horseradish peroxidase (HRP)-conjugated IgG antibody, followed by detection with an enhanced chemiluminescence (ECL)-based technique (13) . Replacement of UCMA solution or the anti-UCMA antibody with BSA solution did not reveal significant signals.
Pulldown assays were performed as previously reported (20) , in which 1 mg/ml type II collagen or BSA was coupled to CNBr-activated Sepharose beads. Thereafter, 20 ml BSASepharose or type II collagen-Sepharose beads was incubated with 2 mg UCMA in 1 ml pulldown buffer (20 mM Tris, pH 8.0, 25 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1% Triton X-100, 1 mM dithiothreitol) overnight at 48C. After washing, coprecipitated UCMA was detected by Western blotting using a mouse anti-FLAG antibody. For solid-phase binding assays, enzyme-linked immunosorbent assay (ELISA) plates were coated with BSA (blanks; 10 mg/well) or collagens (1-10,000 ng/well). After blocking with BSA, the plates were incubated with UCMA (100 ng/ml). Bound UCMA was detected using a mouse anti-FLAG antibody (1:1,000) or an HRP-conjugated anti-mouse IgG antibody, followed by detection with an ABTS-based colorimetric technique at 405 nm.
Cartilage explant cultures. Mouse articular cartilage explants were obtained from the femoral heads of 3-week-old Ucma-deficient mice and WT littermates, as reported previously (21) . Each cartilage specimen was cultured in 100 ml Dulbecco's modified Eagle's medium-Ham's F-12 for 1-3 days, with or without stimulants. To study the degradation of collagen and aggrecan, cartilage explants were treated with 10 ng/ml interleukin-1b (IL-1b) for 3 days (n 5 5 samples) or with 50 nM recombinant MMP-1 (n 5 2-3 samples) or 20 nM recombinant ADAMTS-5 (n 5 5 samples or n 5 3 samples) (all from PeproTech) for 24 hours (21, 22) . Afterward, conditioned medium was collected and cartilage specimens were extracted with 125 mg/ml papain at 608C overnight to release residual collagens and proteoglycans. Quantification of collagens was performed through the detection of hydroxyproline, using a QuickZyme Biosciences Total Collagen Assay. The amount of released collagen was normalized against the total collagen content in the conditioned medium and papain extracts.
Proteoglycans were quantified by applying a dimethylmethylene blue-based dye binding assay (21) , in which 250 ml dye solution (16 mg/ml dimethylmethylene blue in 0.5% ethanol, 2 gm/liter sodium formate, 0.2% formic acid) was added to 40 ml of sample, and absorption was measured at 595 nm, with a reference wavelength of 655 nm. The amount of released proteoglycan was normalized against the total proteoglycan content in the conditioned medium and papain extracts.
Aggrecanase activity assay. UCMA-dependent inhibition of aggrecanase activity was performed using an Aggrecanase Activity ELISA system (MD Biosciences) according to the manufacturer's instructions. A synthetic aggrecan interglobular domain was subjected to proteolytic cleavage with 0.75 nM recombinant ADAMTS-4 (MD Biosciences) or 1 nM ADAMTS-5 (PeproTech) in the presence of varying amounts of recombinant UCMA for 15 minutes at 378C. Finally, aggrecan cleavage products were quantified using an ELISA that detects the aggrecan neoepitope ARGSVIL.
Osteoclast differentiation assays. Osteoclast progenitors were isolated from the bone marrow of 6-week-old C57BL/6 mice. For differentiation of osteoclasts, 5 3 10 5 cells/cm 2 were cultured in a-minimum essential medium containing 10% fetal calf serum, 1% penicillin-streptomycin, 30 ng/ml macrophage colony-stimulating factor (M-CSF) (PeproTech), 10 ng/ml RANKL (PeproTech), and varying doses of recombinant UCMA (13). After 5 days of differentiation, TRAP staining was performed using a leukocyte acid phosphatase kit (Sigma-Aldrich).
For analysis of osteoclastogenesis-related signaling pathways, the cells were differentiated for only 3 days. Thereafter, the cells were starved overnight in serum-free medium before stimulation with recombinant UCMA. For coculture experiments, WT mouse bone marrow cells were differentiated with M-CSF and only 5 ng/ml RANKL in the presence of femoral articular cartilage explants from 3-week-old Ucma-deficient and WT mice (n 5 3 mice per group).
Western blotting. Analyses by Western blotting were performed as reported previously (23) . Cell lysates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After blotting, levels of phosphorylated and total IKKa/b, p38 MAPK, and ERK-1/2 were detected using their respective primary rabbit antibodies (each 1:1,000; Cell Signaling Technologies), an HRP-conjugated anti-rabbit IgG antibody, and an ECL-based detection technique.
Statistical analysis. Data are presented as the mean 6 SEM. Statistically significant differences between 2 groups were evaluated by Mann-Whitney test. When more than 2 groups were compared, one-way analysis of variance and Tukey's test for multiple comparisons were used, after confirming normal distribution of the data using the Kolmogorov-Smirnov test. Results were analyzed using GraphPad Prism software.
RESULTS
Overexpression of UCMA in osteoarthritic cartilage. We have previously demonstrated the cartilagespecific expression of UCMA during mouse development (12, 13 ). In the current study, we confirmed this finding using reporter mice that harbor a lacZ cassette replacing exon 1 of the Ucma gene (12 UCMA protein was found in both the articular cartilage and growth plate cartilage, but not in the bone, of adult mice. While Ucma-expressing chondrocytes appeared to be located primarily within the resting and proliferative zones or above the tidemark, UCMA protein was also detected in calcified cartilage in the vicinity of the bone (see Supplementary Figure 1J , http://onlinelibrary.wiley.com/ doi/10.1002/art.ART40042/abstract).
To investigate a potential role of UCMA in osteoarthritis, we studied UCMA expression in healthy and osteoarthritic human articular cartilage. While Ucma mRNA levels did not significantly differ between healthy and osteoarthritic human cartilage samples (data not shown), UCMA protein was substantially overexpressed in human osteoarthritic cartilage, particularly at chondrones (chondrocyte clusters) in severely affected cartilage areas ( Figure 1A, part d) . In the mouse model, induction of osteoarthritis by DMM in mice at ages 8 weeks ( Figure 1B were assessed after sham or DMM surgery in WT and Ucma-deficient mice. E-H, Levels of the matrix metalloproteinase-generated VDIPEN and ADAMTS-generated NITEGE aggrecan neoepitopes were assessed by immunohistochemistry (E and F) and quantified as the percentage of positive cells (G and H). I-K, The extent of cell death was assessed in mouse tibial articular cartilage samples by determining the number of empty lacunae in hematoxylin and eosin (H&E)-stained sections (I and K) and by TUNEL staining for apoptotic cells (J and K). In K, the lower line delineates the cement line, while the upper line indicates the tidemark. Black arrows indicate empty lacunae, and the white arrow indicates a TUNEL1 chondrocyte above the tidemark. Counterstaining was done with DAPI. Results are the mean 6 SEM of $5 mice per group (;300-500 chondrocytes per joint). * 5 P , 0.05; ** 5 P , 0.01; *** 5 P , 0.001. See Figure 1 for other definitions.
sections from Ucma-deficient mice confirmed the signal specificity (Supplementary Figure 1J , http://onlinelibrary. wiley.com/doi/10.1002/art.ART40042/abstract).
Aggravation of osteoarthritis-triggered cartilage damage in Ucma-deficient mice. We next studied the functional role of UCMA in osteoarthritic mice. Osteoarthritis was induced by DMM in 8-week-old Ucma-deficient and WT mice. Eight weeks after surgery, Ucma-deficient mice exhibited significantly higher OARSI scores for osteoarthritis severity compared to WT littermates (Figures 2A and B) , along with increased proteoglycan loss ( Figure 2C ) and reduced articular cartilage thickness ( Figure 2D ). DMM surgery in 12-week-old mice resulted in similar findings at 4 and 8 weeks after surgery (see Supplementary Figure 3 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.ART40042/abstract). These findings demonstrate that Ucma-deficient mice are more prone to osteoarthritis-triggered cartilage damage than that seen in WT mice, indicating that UCMA has potential chondroprotective effects.
Ucma-deficient mice with osteoarthritis exhibited significantly decreased levels of mRNA for the tissue inhibitor of metalloproteinases 2 (TIMP-2) gene, but the expression of other anabolic and catabolic chondrocyte genes, such as Aggrecan, Col2a1, Col10a1, ADAMTS4, ADAMTS5, MMP3, MMP9, MMP13, Timp1, and Timp3, were not altered in the epiphyseal cartilage from newborn mice or in the complete knee joints or articular knee cartilage from mice at 8 weeks after surgery (results in Supplementary  Figures 4A-L Figures 2F and H) in articular cartilage confirmed that DMM-induced aggrecan degradation was enhanced in Ucma-deficient mice, which is consistent with our observations of increased proteoglycan loss in these mice. Thus, UCMA may inhibit proteoglycan-degrading enzymes such as aggrecanases.
Protection of cartilage from ADAMTS-dependent aggrecan cleavage and inhibition of ADAMTS-dependent aggrecanase activity by UCMA. To investigate whether UCMA may affect the stability of cartilage by interfering with proteolytic activity, we explanted femoral articular cartilage from 3-week-old WT and Ucma-deficient mice and analyzed the susceptibility of the cartilage to IL-1b-induced degradation after 3 days of in vitro culture. IL-1b-induced proteoglycan release was significantly higher in cartilage explants from Ucma-deficient mice than in explants from WT littermates ( Figure 3A, part a) .
We next tested the direct susceptibility of the articular cartilage to proteolytic cleavage, in analyses of cartilage explants from Ucma-deficient mice and WT littermates. Cartilage explants were subjected to collagen or aggrecan cleavage by recombinant MMP-1 or ADAMTS-5. WT and Ucma-deficient mouse cartilage did not differ in its susceptibility to MMP-1-mediated collagen cleavage ( Figure 3B , part e), but Ucma-deficient mouse cartilage explants exhibited a significantly higher level of ADAMTS-5-triggered proteoglycan cleavage ( Figure 3A, part b) .
In order to investigate whether UCMA directly affects the proteolytic activity of ADAMTS aggrecanases, a synthetic peptide containing an ADAMTS cleavage site was subjected to ADAMTS-4 or ADAMTS-5 digestion in the absence or presence of recombinant UCMA. Aggrecanase activity was determined by the generation of an ADAMTSspecific aggrecan cleavage product, ARGSVIL. In fact, UCMA blocked the proteolytic activity of both ADAMTS-4 ( Figure 3A , part c) and ADAMTS-5 ( Figure 3A , part d) in a dose-dependent manner, reaching up to ;90% inhibition, suggesting that UCMA serves as a physiologic inhibitor of aggrecanases.
Direct interaction of UCMA with collagens in the cartilage matrix. Although our data show that UCMA does not inhibit collagen degradation by MMP-1, the possibility exists that UCMA may protect cartilage collagen fibrils indirectly by masking proteolytic cleavage sites. We had previously shown, by electron microscopy, that UCMA is associated with collagen fibrils in the cartilage matrix (13) . We confirmed this finding in the present study, using another antibody (UCMA ab2) for immunogold labeling and subsequent detection by electron microscopy (see results in Supplementary Figure 7 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.ART40042/abstract).
To investigate whether UCMA directly binds to collagens, we immobilized different collagen types on PVDF membranes and incubated these blots with recombinant FLAG-tagged UCMA. Detection of bound UCMA using an anti-FLAG or anti-UCMA antibody revealed that UCMA directly interacts with cartilage-specific collagens, including type II and type XI collagens. In contrast, UCMA did not bind to type I collagen, which is the typical process seen in bone, tendon, and skin ( Figure 3B , parts a and b).
UCMA binding to type II collagen was also confirmed in a pulldown assay using type II collagen-coupled Sepharose beads ( Figure 3B, part c) . Solid-phase assays using collagen-coated ELISA plates and UCMA in the liquid phase further confirmed these findings ( Figure 3B , part d), suggesting that UCMA may be integrated in the cartilage matrix. 1238 STOCK ET AL Figure 3 . Blockade of ADAMTS-triggered aggrecanolysis by UCMA, and interaction of UCMA with type II collagen (Col II). A, Effects of UCMA on ADAMTS-dependent aggrecanase activity were assessed in articular cartilage explants from wild-type (WT) mice (n 5 5) and Ucmadeficient (knockout [KO]) mice (n 5 5 or n 5 3) after culture with 10 ng/ml interleukin-1b (IL-1b) for 3 days (part a) or with 20 nM ADAMTS-5 for 24 hours (part b). IL-1b-dependent (dep.) or ADAMTS-dependent proteoglycan (PG) release into the medium was determined relative (rel.) to total proteoglycan content. The activity of ADAMTS-4 (part c) and ADAMTS-5 (part d) in the presence of 0-1,000 ng/ml UCMA was determined using an enzyme-linked immunosorbent assay (ELISA)-based system. Results are the mean 6 SEM. B, Collagen types were blotted onto a PVDF membrane and incubated with a recombinant His-FLAG-tagged UCMA. Binding of UCMA to the various collagens was detected with an anti-FLAG antibody (part a) or an anti-UCMA antibody (parts a and b). Staining with Coomassie blue demonstrates equal loading. Coprecipitation of FLAG-tagged UCMA with bovine serum albumin (BSA)-or type II collagen-coupled Sepharose beads was detected by Western blotting using an anti-FLAG antibody (part c). The various collagens were coated to ELISA plates at the indicated doses and incubated with UCMA, and bound UCMA was detected with an anti-FLAG antibody and a colorimetric detection system (part d). Results are the mean 6 SEM of 3 independent experiments. Articular cartilage explants from WT mice (n 5 3) and Ucma-deficient mice (n 5 2) were incubated with 50 nM matrix metalloproteinase 1 (MMP-1) for 24 hours, and the percentage of released hydroxyproline (measured as collagen was determined in relation to total hydroxyproline content (part e). Results are the mean 6 SEM. * 5 P , 0.05; ** 5 P , 0.01; *** 5 P , 0.001. NS 5 not significant (see Figure 1 for other definitions). Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40042/abstract.
Increased chondrocyte cell death in Ucma-deficient mice with osteoarthritis. Enhanced chondrocyte apoptosis can also contribute to osteoarthritis-related cartilage damage. To estimate the number of dying and dead chondrocytes in the articular cartilage of Ucma-deficient and WT mice after sham surgery or DMM surgery, we quantified the numbers of empty lacunae and TUNELpositive cells. Intriguingly, DMM-operated Ucma-deficient mice exhibited a significant increase in the number of empty lacunae ( Figures 2I and K) and also a significant increase in the number of TUNEL-positive cells ( Figures  2J and K) . While most of the TUNEL-positive cells were located in the calcified zone, we also observed more TUNEL-positive cells in the noncalcified cartilage from Ucma-deficient mice after DMM surgery.
Alleviation of osteophyte formation and subchondral bone sclerosis by Ucma deficiency during experimental osteoarthritis. Osteophyte formation and bone sclerosis are hallmarks of osteoarthritis. Overexpression of UCMA in osteoarthritic articular cartilage and its accumulation at the bone-cartilage interface suggest that UCMA may also influence subchondral bone during osteoarthritis. Therefore, we investigated the subchondral bone of WT and Ucma-deficient mice after sham or DMM surgery. Profound osteophyte formation was observed at 8 weeks after DMM surgery in 8-week-old WT mice. In Ucma-deficient mice, however, osteophyte formation was substantially reduced after DMM surgery ( Figures 4A and B) . Moreover, we observed significant thickening of the subchondral bone plate and increased bone volume in the tibial primary spongiosa in 8-week-old WT animals after DMM surgery, whereas these parameters remained unchanged in DMM-operated Ucma-deficient mice (Figures 4C and D) . Similar findings were seen in 12-week-old mice at 8 weeks postsurgery, whereas at 4 weeks postsurgery, differences in bone in 12-week-old mice were not yet detectable (see results in Supplementary Figures 8A-H , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.ART40042/abstract).
Bone volume in the metaphyseal region of the tibia, excluding the primary spongiosa, was not significantly altered by DMM surgery in either the WT or Ucma-deficient mice ( Figure 4E ). These results demonstrate that Ucma deficiency alleviates subchondral bone sclerosis in DMM-induced osteoarthritis.
The numbers of osteoblasts and osteoclasts, as well as the osteoblast and osteoclast surface, were significantly increased in WT mice during experimental osteoarthritis, indicating that bone remodeling activity is enhanced in DMM-operated joints. In contrast, Ucma-deficient mice did not exhibit elevated osteoblast or osteoclast counts after DMM surgery ( Figures 5A-C and E-G) . The increase in osteoblast counts during osteoarthritis in WT mice, but not in Ucma-deficient animals, was also reflected by the elevated osteocalcin mRNA levels in the knee joint tissue from WT mice compared to Ucma-deficient mice after DMM surgery ( Figure 5D ). Interestingly, however, there were no significant changes in the levels of mRNA for RANKL and osteoprotegerin (OPG) in associaton with the changes in osteoclast numbers ( Figures 5H and I) . Thus, the RANKL:OPG ratio may not be the decisive factor responsible for changes in Figure 4 . Development of substantially reduced levels of bone sclerosis in Ucma-deficient mice with experimental OA. A, The subchondral bones of sham-operated or DMM-operated wild-type (WT) and Ucma-deficient mice were analyzed for histomorphometric features. B, Osteophyte size at the medial tibia was determined in each group of mice. C-E, Subchondral bone plate thickness (SCBP Th.) (C), bone volume (measured as bone volume/total volume [BV/TV]) of the primary spongiosa (prim. Spong.) (D), and trabecular bone volume (BV/TV) of the metaphysis (the first 4 mm below the primary spongiosa) (E) were determined by micro-computed tomography in each group of mice. Results are the mean 6 SEM of $5 mice per group. ** 5 P , 0.01; *** 5 P , 0.001. NS 5 not significant (see Figure 1 for other definitions). Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40042/abstract. osteoclast numbers after DMM in mice. These data suggest an UCMA-dependent, but RANKL/OPG-independent, mechanism that promotes osteoclastogenesis during experimental osteoarthritis.
Promotion of osteoclast differentiation by UCMA in vitro. To investigate whether UCMA directly affects osteoclastogenesis, we studied the impact of UCMA on osteoclast differentiation in vitro. When WT mouse bone marrow cells were cocultured with WT mouse articular cartilage explants, differentiation of osteoclasts was substantially promoted in close proximity to the explants. This effect decreased with increasing distance from the explants, suggesting a gradient of effect. In cocultures with cartilage explants from Ucma-deficient mice, however, cartilage-dependent promotion of osteoclastogenesis was substantially reduced (Figures 6A-C) . These data indicate that UCMA gets released from cartilage at biologically active levels, which, although too low to detect biochemically (see Supplementary  Figure 9 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.ART40042/ abstract), can support the differentiation of osteoclasts outside the cartilage compartment. Accordingly, recombinant Figure 5 . Reduced numbers of osteoblasts and osteoclasts during experimental OA in Ucma-deficient mice. Osteoblast and osteoclast counts were determined by histomorphometry in the primary spongiosa and proximal metaphysis of wild-type (WT) and Ucma-deficient mice after sham surgery or DMM surgery. A and E, Tibial sections were stained for osteoblasts and osteoclasts with Goldner's trichrome (A) or tartrateresistant acid phosphatase (E). B-D, Osteoblast numbers (measured as osteoblasts per bone perimeter [ObN/BPm]) (B), osteoblast surface per bone surface (ObS/BS) (C), and expression of the osteocalcin gene (D) were determined in each group of mice postsurgery. F-I, Osteoclast numbers (measured as osteoclasts per bone perimeter [OcN/BPm]) (F), osteoclast surface per bone surface (OcS/BS) (G), and expression of Rankl (H) and Opg (I) were determined in each group of mice postsurgery. Relative (rel.) gene expression was determined by reverse transcriptionpolymerase chain reaction. Results are the mean 6 SEM of $5 mice per group. * 5 P , 0.05; ** 5 P , 0.01; *** 5 P , 0.001. NS 5 not significant (see Figure 1 for other definitions).
UCMA also promoted osteoclastogenesis in vitro ( Figures  6D and E) . We did not detect interactions between UCMA and RANKL/OPG (results in Supplementary Figure 10 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.ART40042/abstract), which might have explained this finding.
Moreover, UCMA induced the phosphorylation of ERK-1/2 and p38 MAPK, but not that of IKKa/b, in Figure 6 . Promotion of osteoclast differentiation in vitro by upper zone of growth plate and cartilage matrix-associated protein (UCMA). A-C, Wild-type (WT) mouse bone marrow-derived osteoclast precursors were cocultured with cartilage explants from WT or Ucma-deficient (knockout [KO]) mice (n 5 3 mice per group). Osteoclast numbers were evaluated by tartrate-resistant acid phosphatase (TRAP) staining at various distances from the cartilage explants (Cart radius 1-4 [r1-4]) (A). Osteoclast-cartilage explant cocultures were assessed by TRAP staining at r1-4 (B), and osteoclasts were quantified as the osteoclast number per field of vision (OcN/FOV) at r1-4 (C). D and E, Induction of osteoclastogenesis by recombinant UCMA was evaluated using TRAP staining of osteoclasts (D) and quantification of TRAP-positive multinucleated cells (E) in cell cultures with various doses of recombinant (rec.) UCMA. F, Western blotting was used to assess the levels of total and phosphorylated p38 MAP kinase and ERK-1/2 in osteoclast precursors incubated with recombinant UCMA (500 ng/ml) for the indicated periods of time (in minutes). All experiments were repeated at least twice. Results are the mean 6 SEM. * 5 P , 0.05; ** 5 P , 0.01; *** 5 P , 0.001. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40042/abstract. osteoclast precursors in a RANKL-independent manner ( Figure 6F ). This finding indicates that UCMA may have direct activating effects on osteoclasts via the stimulation of signaling pathways, which thereby promotes osteoclastogenesis. These findings support the notion that UCMA induces subchondral bone turnover during osteoarthritis.
DISCUSSION
UCMA (also termed Gla-rich protein) has been reported to accumulate in calcified cartilage during osteoarthritis (24) . Herein, we extended this concept, showing that UCMA is particularly overexpressed in newly forming chondrocyte clusters in the osteoarthritic cartilage. So far, the physiologic role of UCMA is largely unknown. During zebrafish development, knockdown of Ucma disturbs skeletal development and leads to craniofacial malformations (15) . In contrast, ablation of Ucma in the mouse does not affect skeletal development (12) .
In this study, we challenged articular cartilage integrity through surgical induction of osteoarthritis. Observations of exacerbated cartilage damage in Ucma-deficient mice suggest that UCMA has a chondroprotective effect. This finding also demonstrates that mechanisms compensating for the loss of UCMA during normal cartilage development cannot countervail the loss of UCMA during osteoarthritis. Interestingly, aggravated cartilage damage in Ucma-deficient mice was not associated with significant changes in the expression of anabolic or catabolic cartilage genes, except for a decrease in Timp2 mRNA expression. Reduced Timp2 expression may contribute to the cartilage phenotype seen in Ucma-deficient mice, since TIMP-2 can inhibit MMPs, and Timp2-deficient mice develop aggravated DMM-induced cartilage damage (20, 21) . However, in Timp2-deficient mice, augmented cartilage degradation was found to be associated with increased angiogenesis and osteophyte formation, both of which are events that are unlikely to result from enhanced cartilage proteolysis in the absence of TIMP-2 (21). In contrast, in Ucma-deficient mice, osteophyte formation was substantially reduced. Moreover, ADAMTS-related aggrecan cleavage was increased. Studies have shown that TIMP-2 does not block ADAMTS activity (20, 25) , and therefore, decreased Timp2 mRNA levels cannot fully explain the observed phenotype in Ucma-deficient osteoarthritic mice.
We hypothesized that UCMA may exert its chondroprotective effect, at least partially, by increasing the resistance of the cartilage matrix against proteolytic degradation. In fact, we had previously shown that chondrocytes secrete UCMA into the cartilage matrix, where it colocalizes with collagen fibrils (13) . Herein we demonstrated that UCMA directly interacts with different cartilagespecific collagen types, including type II collagen. Several studies have indicated that the ablation of collagen-binding cartilage matrix proteins increases the vulnerability of articular cartilage. For example, deletion of matrilin 3 or type IX collagen in mice and mutations in cartilage oligomeric matrix protein in humans will result in early onset of osteoarthritis (26) (27) (28) (29) . Accordingly, Ucma-deficient mouse cartilage was more susceptible to IL-1b-induced proteoglycan degradation, thus supporting our finding of increased proteoglycan loss in the articular cartilage of Ucma-deficient mice during experimental osteoarthritis.
Moreover, while Ucma deficiency did not directly affect MMP-triggered collagen degradation, Ucma-deficient mouse cartilage was significantly more sensitive to ADAMTS-5-dependent aggrecan cleavage. This effect could be explained either by the increased accessibility of proteoglycans or by the elevated aggrecanase activity in Ucma-deficient mouse cartilage. Our analysis of the effect of UCMA on aggrecanase activity clearly showed that UCMA blocked the aggrecanase activity of both ADAMTS-4 and ADAMTS-5. Therefore, along with TIMP-3, UCMA can be considered to be one of the few endogenous inhibitors of ADAMTS aggrecanases. In consequence, the observed overexpression of UCMA during osteoarthritis represents a type of rescue mechanism to reduce aggrecanase activity in diseased cartilage (25) .
Apart from enhanced cartilage matrix degradation, chondrocyte apoptosis has also been suggested to be a factor promoting cartilage damage in osteoarthritis (6, 7) . In fact, we observed significantly increased chondrocyte death in the articular cartilage from Ucma-deficient mice compared to WT controls after DMM surgery. The increase in cell death was observed throughout the articular cartilage, in which UCMA protein is normally detected, although the majority of cell death was confined to the calcified cartilage. Apoptosis in articular cartilage has been associated with matrix degradation during osteoarthritis. Chondrocyte-specific deletion of MMP-13 leads to decreased matrix degradation and apoptosis during osteoarthritis (30, 31) . Similarly, Ucma-deficient mice showed an increase in MMP-generated matrix degradation and chondrocyte cell death, although a causal relationship between both events was not shown.
Bone changes are another hallmark of osteoarthritis and have been associated with high local bone turnover (32) . Cartilage and bone changes are tightly coupled in osteoarthritic joints, but the molecular mechanisms of cartilage-bone interactions are not completely understood. Osteoblasts have been shown to induce phenotypic changes in human osteoarthritic chondrocytes. Osteoclasts have been associated with osteoarthritis-related cartilage destruction (11, 33, 34) . Likewise, several bone-derived factors that potentially influence cartilage in osteoarthritis have been identified, such as transforming growth factor b, IL-6, RANTES, and monocyte chemotactic protein 1 (10, 11, 33, (35) (36) (37) . Nonetheless, concepts that might explain how cartilage affects bone are scarcely understood to date.
Herein we show not only that cartilage is the major source of UCMA but also that UCMA is secreted into the cartilage matrix, in which it may migrate to the cartilagebone interface (12) (13) (14) . UCMA-collagen interactions may regulate this diffusion through the matrix, which is similar, for example, to the control of Indian hedgehog migration in the cartilage matrix through binding to proteoglycans (38) . Accumulation of UCMA in the calcified matrix may be mediated by the binding of calcium via Gla residues on UCMA (24) . At the cartilage-bone interface, UCMA may directly act on osteoclasts and influence bone homeostasis. Intriguingly, we observed that osteoarthritis-related changes in the subchondral bone, such as osteophyte formation and bone sclerosis, were alleviated in Ucma-deficient mice. UCMA-dependent effects on bone were, however, only detectable in close proximity to cartilage, but not at higher distances from the cartilage.
It was previously demonstrated that UCMA affects osteogenic differentiation in vitro, although osteoblast counts and differentiation of osteoblasts in Ucma-deficient mice are not altered during normal development (12, 13, 39) . Elevated osteoblast counts in the subchondral bone compartment could only be detected in WT mice, but not in Ucma-deficient mice, indicating that UCMA may promote osteoblast differentiation during osteoarthritis. This supports the findings in a study by Lee and colleagues, who found that overexpression of UCMA in osteoblast precursors stimulates osteogenic differentiation (39). Although we had previously observed an inhibitory effect of recombinant UCMA on osteogenic differentiation in vitro, this difference may be explained by alterations in posttranslational modifications of recombinant UCMA, such as proteolytic processing, tyrosine sulfation, and Gla residues, or could be explained by the stage of differentiation (13, 14, 39, 40) .
Osteoclast numbers were increased in WT mice but not in Ucma-knockout mice. Analysis of cartilage organ cultures revealed that UCMA was secreted from the cartilage into the conditioned medium. WT mouse cartilage explants, but not cartilage explants from Ucmadeficient mice, promoted in vitro osteoclast differentiation, indicating that UCMA is released from cartilage at levels sufficient to promote osteoclastogenesis. We did not detect interaction of UCMA with either RANKL or OPG; however, UCMA rapidly induced the p38 MAPK and ERK signaling pathways, both of which are essential for osteoclast differentiation (41, 42) . This finding suggests that UCMA directly activates osteoclast differentiation by an as yet-unknown receptor, which in turn activates proosteoclastic signaling pathways.
In conclusion, we herein describe a dual role of UCMA in osteoarthritis. Our findings show that UCMA supports, on the one hand, the integrity of the articular cartilage by controlling aggrecanase activity, while on the other hand, it promotes osteoarthritis-related bone responses.
